BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 20878588)

  • 21. Particulate delivery systems for animal vaccines.
    Scheerlinck JP; Greenwood DL
    Methods; 2006 Sep; 40(1):118-24. PubMed ID: 16997719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Laser vaccine adjuvants. History, progress, and potential.
    Kashiwagi S; Brauns T; Gelfand J; Poznansky MC
    Hum Vaccin Immunother; 2014; 10(7):1892-907. PubMed ID: 25424797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A need for effective adjuvants.
    Bunce CJ; Morse MA
    Curr Opin Mol Ther; 2003 Feb; 5(1):8-9. PubMed ID: 12669464
    [No Abstract]   [Full Text] [Related]  

  • 24. Adjuvants and delivery systems for antifungal vaccines: current state and future developments.
    Portuondo DL; Ferreira LS; Urbaczek AC; Batista-Duharte A; Carlos IZ
    Med Mycol; 2015 Jan; 53(1):69-89. PubMed ID: 25362733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carbohydrate-based vaccine adjuvants - discovery and development.
    Hu J; Qiu L; Wang X; Zou X; Lu M; Yin J
    Expert Opin Drug Discov; 2015 Oct; 10(10):1133-44. PubMed ID: 26372693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The path forward.
    De Gregorio E
    Vaccine; 2015 Jun; 33 Suppl 2():B60-3. PubMed ID: 26022572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gaps in knowledge and prospects for research of adjuvanted vaccines.
    Seder R; Reed SG; O'Hagan D; Malyala P; D'Oro U; Laera D; Abrignani S; Cerundolo V; Steinman L; Bertholet S
    Vaccine; 2015 Jun; 33 Suppl 2():B40-3. PubMed ID: 26022566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Innovations in vaccine development: can regulatory authorities keep up?
    Cox MM; Onraedt A
    Expert Rev Vaccines; 2012 Oct; 11(10):1171-3. PubMed ID: 23176649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.
    Garçon N; Van Mechelen M
    Expert Rev Vaccines; 2011 Apr; 10(4):471-86. PubMed ID: 21506645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delivery technologies for human vaccines.
    Moingeon P; de Taisne C; Almond J
    Br Med Bull; 2002; 62(1):29-44. PubMed ID: 12176848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunomodulatory biomaterials.
    Mallapragada SK; Narasimhan B
    Int J Pharm; 2008 Dec; 364(2):265-71. PubMed ID: 18662761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene Based Vaccines: Optimising Development and Delivery - A marcus evans Conference.
    Garren H
    IDrugs; 2010 Nov; 13(11):759-61. PubMed ID: 21046520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT
    Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.
    Drane D; Gittleson C; Boyle J; Maraskovsky E
    Expert Rev Vaccines; 2007 Oct; 6(5):761-72. PubMed ID: 17931156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Saponin-adjuvanted particulate vaccines for clinical use.
    Skene CD; Sutton P
    Methods; 2006 Sep; 40(1):53-9. PubMed ID: 16997713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in vaccine delivery.
    Cordeiro AS; Alonso MJ
    Pharm Pat Anal; 2016; 5(1):49-73. PubMed ID: 26667309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New horizons in adjuvants for vaccine development.
    Reed SG; Bertholet S; Coler RN; Friede M
    Trends Immunol; 2009 Jan; 30(1):23-32. PubMed ID: 19059004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.
    Maraskovsky E; Schnurr M; Wilson NS; Robson NC; Boyle J; Drane D
    Immunol Cell Biol; 2009 Jul; 87(5):371-6. PubMed ID: 19381160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PepTalk--CHI's Ninth Annual Meeting--Engineering Protein & Peptide Therapeutics: Peptides.
    Craik D
    IDrugs; 2010 Mar; 13(3):156-8. PubMed ID: 20191429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies to link innate and adaptive immunity when designing vaccine adjuvants.
    Garlapati S; Facci M; Polewicz M; Strom S; Babiuk LA; Mutwiri G; Hancock RE; Elliott MR; Gerdts V
    Vet Immunol Immunopathol; 2009 Mar; 128(1-3):184-91. PubMed ID: 19042032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.